IDEXX Laboratories, Inc. $IDXX Position Lowered by Glenview Trust Co

Glenview Trust Co decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,003 shares of the company’s stock after selling 3,704 shares during the quarter. Glenview Trust Co’s holdings in IDEXX Laboratories were worth $9,401,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of New York Mellon Corp bought a new position in IDEXX Laboratories in the second quarter valued at about $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of IDEXX Laboratories by 4.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after purchasing an additional 39,700 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of IDEXX Laboratories by 52.4% during the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after purchasing an additional 288,471 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of IDEXX Laboratories by 4.3% during the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock worth $322,145,000 after purchasing an additional 23,582 shares during the last quarter. Finally, Alyeska Investment Group L.P. increased its stake in shares of IDEXX Laboratories by 97.3% in the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after buying an additional 197,808 shares during the period. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 4.3%

Shares of IDEXX Laboratories stock opened at $551.21 on Friday. IDEXX Laboratories, Inc. has a one year low of $500.61 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The stock’s 50-day moving average is $534.27 and its 200 day moving average is $574.09. The firm has a market cap of $43.42 billion, a price-to-earnings ratio of 38.76 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The firm’s revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the firm posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Insider Activity at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares of the company’s stock, valued at $5,090,941.44. This trade represents a 18.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 0.79% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on IDXX shares. The Goldman Sachs Group began coverage on shares of IDEXX Laboratories in a report on Friday, October 16th. They issued a “buy” rating and a $740.00 price objective for the company. KeyCorp began coverage on shares of IDEXX Laboratories in a report on Monday, October 12th. They set a “sector weight” rating on the stock. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. decreased their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research report on Friday, October 16th. Finally, Barclays dropped their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Eight analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $721.67.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.